(MENAFN- EIN Presswire) Clostridium Difficile Infections companies working in market are Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals. LAS VEGAS ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

HealthDay News — For patients with type 1 diabetes with moderate-to-severe gastrointestinal symptoms, fecal microbiota transplantation (FMT) is safe and improves clinical outcomes, according to a ...

Among 547 episodes of C difficile infection documented in cancer patients in Australia and Spain, 50% were severe, and the 90 ...

The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial ...

Idorsia will conduct a proof-of-concept study for patients with vitiligo. Unique precision medicine with a dual targeting of ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...

Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland - January 15 ...